Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 147, Issue 4, 2009, Pages 507-514

  Blum, Kristie A ^a   Advani, Anjani ^b   Fernandez, Louis ^c   Van Der Jagt, Richard ^d   Brandwein, Joseph ^e   Kambhampati, Suman ^f   Kassis, Jeannine ^g   Davis, Melanie ^a   Bonfils, Claire ^h   Dubay, Marja ^h   Dumouchel, Julie ^h   Drouin, Michel ^h   Lucas, David M ^a   Martell, Robert E ^h   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h METHYLGENE INC   (Canada)

Author keywords

Chronic lymphocytic leukaemia; Epigenetics; Histone deacetylase inhibitors; MGCD0103

Indexed keywords

FLUDARABINE; HISTONE H3; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BACTERIAL MENINGITIS; BRADYCARDIA; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EPIDIDYMITIS; EXTERNAL OTITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULITIS; HALLUCINATION; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN CELL; HYPERTENSION; HYPOKALEMIA; INFECTION; INFLUENZA; LEUKEMIA CELL; LEUKOPENIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIS INFECTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; ORCHITIS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; RESPIRATORY DISTRESS; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CHROMOSOME ABERRATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME;

EID: 70350448445     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07881.x     Document Type: Article

References (29)

1. Aron, J.L., Parthun, M.R., Marcucci, G., Kitada, S., Mone, A.P., Davis, M., Shen, T., Murphy, T., Wickham, J., Kanakry, C., Lucas, D., Reed, J., Grever, M. Byrd, J.C. (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood, 102, 652 658.
2. Badros, A., Philip, S., Niesvizky, R., Goloubeva, O., Harris, C., Zweibel, J., Wright, J., Burger, A., Grant, S., Baer, M.R. Egorin, M.J. (2007) Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). Blood (American Society of Hematology Annual Meeting Abstracts), 110, Abstract 1168.
3. Baur, A.S., Shaw, P., Burri, N., Delacretaz, F., Bosman, F. Chaubert, P. (1999) Frequent methylation silencing of p15/INK4b (MTS2)and p16/INK4a (MTS1) in B-cell and T-cell lymphomas. Blood, 94, 1773 1781.
4. Blum, K.A., Liu, Z., Lucas, D.M., Baiocchi, R., Lin, T.S., Benson, D., Devine, S.M., Jones, J., Andritsos, L., Flynn, J., Cheng, P., Xie, Z., Marcucci, G., Chan, K.K., Grever, M.R. Byrd, J.C. (2008) A phase I evaluation of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): dose-limiting myelosuppression without evidence of hypomethylation. Blood (American Society of Hematology Annual Meeting Abstracts), 112, Abstract 3169.
5. Bociek, R., Kuruvilla, J., Pro, B., Wedgewood, A., Li, Z., Drouin, M., Patterson, T., Ward, R., Martell, R.E. Younes, A. (2008) Isotype-selective histone deacetylase inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology), 26, 8507 (Abstract).
6. Bokelmann, I. Mahlknecht, U. (2008) Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Molecular Medicine, 14, 20 27.
7. Bonfils, C., Kalita, A., Dubay, M., Siu, L.L., Carducci, M.A., Reid, G., Martell, R.E., Besterman, J.M. Li, Z. (2008) Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clinical Cancer Research, 14, 3441 3449.
8. Byrd, J.C., Shinn, C., Ravi, R., Willis, C.R., Waslenenko, J.K., Flinn, I.W., Dawson, N.A. Grever, M.R. (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood, 94, 1401 1408.
9. Byrd, J.C., Kitada, S., Flinn, I.W., Aron, J.L., Pearson, M., Lucas, D. Reed, J.C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99, 1038 1043.
10. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejaswi, S.L., Binkley, P., Wright, J., Chan, K.K. Grever, M.R. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959 967.
11. Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B., Moran, M., Blum, K.A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L.J., Johnson, A.J., Lucas, D.M., Heerema, N.A., Lozanski, G., Young, D.C., Suarez, J.-R., Colevas, A.D. Grever, M.R. (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109, 399 404.
12. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M., O'Brien, S. Rai, K. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
13. Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L., Robertson, G., Gao, X., Wright, F., Feramisco, J., Peltomaki, P., Lang, J., Schuller, D., Yu, L., Bloomfield, C., Caligiuri, M., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N., Zhang, X., O'Dorisio, M., Held, W., Cavenee, W. Plass, C. (2000) Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nature Genetics, 25, 132 138.
14. Crump, M., Andreadis, C., Assouline, S., Rizzeria, D., Wedgewood, A., McLaughlin, P., Laille, E., Li, Z., Martell, R.E. Younes, A. (2008) Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology), 26, Abstract 8528.
15. Duvic, M., Olsen, E.A., Breneman, D., Pacheco, T.R., Parker, S., Vonderheid, E.C., Ricker, J.L., Rizvi, S., Chen, C., Boileau, K., Cooley, P. Geskin, L.J. (2007) Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). Blood (American Society of Hematology Annual Meeting Abstracts), 110, Abstract 2582.
16. Fournel, M., Bonfils, C., Hou, Y., Yan, P.T., Trachy-Bourget, M.C., Kalita, A., Liu, J., Lu, A.H., Zhou, N.Z., Robert, M.F., Gillespie, J., Wang, J.J., Ste-Croix, H., Rahil, J., Lefebvre, S., Moradei, O., Delorme, D., Macleod, A.R., Besterman, J.M. Li, Z. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics, 7, 759 768.
17. Garcia-Manero, G., Yang, A., Klimek, V., Luger, S., Newsome, W., Berman, N., Patterson, T., Maroun, C., Li, Z., Ward, R. Martell, R.E. (2007) Phase I/II study of the novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology), 25, Abstract 7062.
18. Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W.M., Miller, W.H., Jr., Rousseau, C., Kalita, A., Bonfils, C., Dubay, M., Patterson, T.A., Li, Z., Besterman, J.M., Reid, G., Laille, E., Martell, R.E. Minden, M. (2008a) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 112, 981 989.
19. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V.R., Randolph, S.S., Hardwick, J.S., Reilly, J.F., Chen, C., Ricker, J.L., Secrist, J.P., Richon, V.M., Frankel, S.R. Kantarjian, H.M. (2008b) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111, 1060 1066.
20. Genini, D., Adachi, S., Chao, Q., Rose, D., Carrera, C., Cottam, H., Carson, D. Leoni, L. (2000) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood, 96, 3537 3543.
21. Grant, S., Kolla, S., Sirulnik, L.A., Shapiro, G., Supko, J., Cooper, B., Perkins, E., Ramakrishnan, V., Espinoza-Delgado, I., Tombes, M.B. Roberts, J.D. (2008) Phase I trial of vorinostat (SAHA) in combination with alvocidib (flavopiridol) in patients with relapsed, refractory or (selected) poor prognosis acute leukemia or refractory anemia with excess blasts-2 (RAEB-2). Blood (American Society of Hematology Annual Meeting Abstracts), 112, Abstract 2986.
22. Heider, U., Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Hecht, M., Kleeberg, L., Braun, C., Possinger, K. Sezer, O. (2006) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Blood (American Society of Hematology Annual Meeting Abstracts), 108, Abstract 2509.
23. Hurwitz, H., Nelson, B., O'Dwyer, P., Chiorean, E., Gabrail, N., Li, Z., Laille, E., Drouin, M., Rothenberg, M. Chan, E. (2008) Phase I/II: the oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology), 26, Abstract 4625.
24. Inoue, S., Riley, J., Gant, T.W., Dyer, M.J. Cohen, G.M. (2007) Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia, 21, 1773 1782.
25. Koduru, P.R.K., Zariwala, M., Soni, M., Gong, J., Xiong, Y. Broome, J. (1995) Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p15 in non-Hodgkin's lymphoma. Blood, 86, 2900 2905.
26. Lucas, D.M., Davis, M.E., Parthun, M.R., Mone, A.P., Kitada, S., Cunningham, K.D., Flax, E.L., Wickham, J., Reed, J.C., Byrd, J.C. Grever, M.R. (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 18, 1207 1214.
27. de Ruijter, A.J.M., van Gennip, A.H., Caron, H.N., Kemp, S. Van Kuilenburg, A. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal, 370, 737 749.
28. Siu, L.L., Pili, R., Duran, I., Messersmith, W.A., Chen, E.X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G.K., Li, Z., Kalita, A.M., Laille, E.J., Besterman, J.M., Martell, R.E. Carducci, M.A. (2008) Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of Clinical Oncology, 26, 1940 1947.
29. Zhang, L., Freitas, M.A., Wickham, J., Parthun, M.R., Klisovic, M.I., Marcucci, G. Byrd, J.C. (2004) Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry. Journal of the American Society of Mass Spectrometry, 15, 77 86.